Merck KGaA (MRK) Aktievy
Merck KGaA verkar som ett vetenskaps- och teknikföretag i Tyskland. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 4/6 |
| Framtida tillväxt | 1/6 |
| Tidigare resultat | 1/6 |
| Finansiell hälsa | 5/6 |
| Utdelningar | 5/6 |
Belöningar
Riskanalys
Inga risker upptäckta för MRK från våra riskkontroller.
MRK Community Fair Values
Create NarrativeSee what 79 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Merck KGaA Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | €136.30 |
| 52 veckors högsta | €148.80 |
| 52 veckors lägsta | €100.70 |
| Beta | 0.81 |
| 1 månads förändring | -2.71% |
| 3 månaders förändring | 16.15% |
| 1 års förändring | 21.64% |
| 3 års förändring | -14.30% |
| 5 års förändring | -33.84% |
| Förändring sedan börsintroduktionen | 778.84% |
Senaste nyheter och uppdateringar
Recent updates
Uppdatering av berättelse • Aug 03
MRK: AI Partnerships And Bio-Techne Deal Will Shape Balanced Future Prospects
Analysts have raised their price target for Merck KGaA to €170 from €160, citing slightly higher assumed revenue growth, a modestly higher future P/E of about 22.4, and some pressure on projected profit margins following the agreed cash acquisition of Bio-Techne at €73 per share equivalent. Analyst Commentary Recent research on Merck KGaA is mixed, with analysts weighing the agreed Bio-Techne acquisition price of $73 per share against the company’s longer term growth drivers and current valuation levels.
Uppdatering av berättelse • Jul 20
MRK: Rich Bio Techne Deal And Downgrades Will Restrain Future Returns
Merck KGaA's fair value estimate has been adjusted from €112.00 to €121.00 as analysts factor in updated assumptions on revenue growth, profit margins and discount rates, alongside mixed reactions to the planned Bio Techne acquisition and its potential to support returns only under more optimistic scenarios. Analyst Commentary Recent research on Merck KGaA highlights a shift toward more cautious views, especially around the planned acquisition of Bio Techne and how it could affect valuation, execution risk, and the company’s long term growth profile.
Uppdatering av berättelse • Jul 06
MRK: Bio-Techne Deal And Life Science Recovery Will Drive Future Upside
Analysts have raised their fair value estimate for Merck KGaA from about €172 to roughly €177. This reflects higher blended price targets, even as they note that the planned Bio-Techne acquisition could justify the richer implied future P/E only in more optimistic scenarios.Uppdatering av berättelse • Jun 22
MRK: Life Science Tools Recovery Will Support Future Upside Potential
Analysts recently adjusted their views on Merck KGaA after Street price targets diverged, including a cut to €129 at one firm that now sees a more balanced risk and reward, and a raise to €160 at another firm citing early signs of recovery in life science tools. Analyst Commentary Recent commentary on Merck KGaA reflects a split view, with some bullish analysts highlighting early signs of improvement in key segments such as life science tools, while others see the current share price as broadly aligned with the company's exposure to structural growth drivers.Uppdatering av berättelse • Jun 06
MRK: Life Science Tools Recovery And Lower AI Risk Will Support Upside
Merck KGaA's updated analyst price target now centers around €160, up from €135, with analysts pointing to cautious optimism around life science tools, a more balanced risk and return profile, and sector wide reassessments of recovery potential and valuation. Analyst Commentary Recent research points to a mixed but generally firming stance on Merck KGaA.Uppdatering av berättelse • May 23
MRK: Healthcare Resilience And Raised 2026 Guidance Will Support Future Upside
Narrative Update on Merck KGaA Analysts now see fair value for Merck KGaA at about €143, up from roughly €141, reflecting recent price target revisions and views that healthcare could appeal to investors given the current macro backdrop, geopolitical risks, and perceived lower exposure to AI disruption risks. Analyst Commentary Recent research snapshots show a mixed stance on Merck KGaA, with some analysts trimming price targets and others taking a more neutral starting point.Uppdatering av berättelse • Apr 30
MRK: Healthcare Resilience And Sustainable Solvents Will Support Future Upside
The updated analyst price target for Merck KGaA moves modestly lower to about €141 from around €143, reflecting recent target cuts from firms citing a cautious macro backdrop and sector specific views, while still recognizing potential interest in healthcare as investors weigh geopolitical risk and AI related disruption. Analyst Commentary Recent research on Merck KGaA has focused on recalibrating expectations, with multiple firms trimming price targets and one major house initiating coverage with a neutral stance.Uppdatering av berättelse • Apr 15
MRK: Reset Expectations And 2026 Guidance Will Shape Future Return Balance
Analysts have trimmed the fair value estimate for Merck KGaA from €127.00 to €112.00, reflecting recent reductions in Street price targets and a more cautious stance on profitability, despite slightly higher modeled revenue growth. Analyst Commentary Recent Street research on Merck KGaA has tilted more cautious, with several bearish analysts cutting price targets and reassessing the risk and reward balance.Uppdatering av berättelse • Apr 01
MRK: Lower AI Disruption Risk And Margin Resilience Will Support Future Upside
Analysts have trimmed the fair value estimate for Merck KGaA from €187.48 to €172.13 as recent price target cuts and more cautious ratings have offset slightly higher revenue growth and profit margin assumptions, along with a lower future P/E multiple. Analyst Commentary Recent research shows a mixed set of opinions on Merck KGaA, but with some clear pockets of optimism that help frame the trimmed fair value estimate.Uppdatering av berättelse • Mar 18
MRK: Healthcare Resilience And Limited AI Disruption Will Drive Future Upside
Analysts have trimmed the Merck KGaA fair value estimate from €143.88 to €143.20. This reflects recent cuts to Street price targets in light of a tougher macro backdrop, geopolitical risk and more tempered expectations around sector exposure to AI related disruption.Uppdatering av berättelse • Mar 04
MRK: Margin Resilience And New TGCT Therapy Will Shape Future Upside
Analysts have lifted their price target on Merck KGaA to €130 from €125, citing slightly stronger assumptions for revenue growth, profit margins and future P/E, even as recent rating changes across the sector keep overall views balanced. Analyst Commentary Recent research on Merck KGaA reflects a split view, with some firms turning more cautious while others highlight steady execution and valuation support.Uppdatering av berättelse • Feb 18
MRK: Margin Gains And HPC Buildout Will Shape Future Upside Potential
Analysts have raised their price target on Merck KGaA to €130 from €125, citing updated expectations for slightly lower revenue growth, a modestly higher discount rate, and a small uplift in projected profit margin and future P/E assumptions. Analyst Commentary Recent research on Merck KGaA presents a mixed picture, but there is a clear cluster of constructive views around valuation, profitability, and execution.Uppdatering av berättelse • Feb 03
MRK: Mixed Rating Shifts Will Shape Perceived Balance Of Future Return Potential
Narrative Update: Merck KGaA Analysts have inched their average price target for Merck KGaA up by €5 to €130. This reflects updated views on earnings potential and risk after recent research, including a downgrade at Deutsche Bank and a price target adjustment at Barclays.Uppdatering av berättelse • Jan 20
MRK: Refined Earnings Outlook Points To Balanced Future Return Potential
Analysts have lifted their fair value estimate for Merck KGaA to €127 from €105, citing updated assumptions for revenue growth, profit margins and future P/E multiples that are broadly in line with recent Street target moves, such as the new €130 level from Barclays. Analyst Commentary The recent move to a €130 price target from €125 sits broadly in line with the updated fair value estimate of €127, which suggests that expectations are being fine tuned rather than reset.Uppdatering av berättelse • Jan 06
MRK: Future Earnings Power And HPC Expansion May Support Upside
Narrative Update on Merck KGaA Analysts have trimmed their price target for Merck KGaA by €20 to €130, citing updated assumptions that reflect a fair value of €184.63, a discount rate of 4.93%, revenue growth of 5.19%, a profit margin of 16.10%, and a future P/E of 23.44x. Analyst Commentary Recent Street research signals that analysts are reassessing Merck KGaA's valuation framework, with the latest work reflecting a price target of €130 compared with a prior level of €150.Uppdatering av berättelse • Dec 21
MRK: Future Price Cut Signals Slowing Earnings Momentum Ahead
Analysts have trimmed their price target on Merck KGaA to EUR 130 from EUR 150, reflecting slightly lower long term revenue growth and margin expectations, even as they acknowledge the company's ability to sustain a higher future price to earnings multiple. Analyst Commentary Bearish analysts point to a more challenging backdrop for Merck KGaA, with reduced expectations for long term top line expansion and profitability prompting a reassessment of fair value.Uppdatering av berättelse • Dec 07
MRK: Margin Strength And AI Deal Will Drive Future Upside
Analysts have trimmed their price target on Merck KGaA, cutting it by EUR 20 to EUR 130 as they factor in slightly softer long term revenue growth assumptions, even though profit margin expectations have improved modestly. Analyst Commentary Analysts are recalibrating their views on Merck KGaA, with the reduced price target reflecting a more measured stance on the company’s medium to long term prospects while acknowledging an improved profitability outlook.Uppdatering av berättelse • Nov 23
MRK: New Leadership Change And AI Partnership Will Drive Shares Higher
Analysts have modestly lowered their price target for Merck KGaA from €150 to €130. They cite a combination of slightly reduced profit margin forecasts and an increased discount rate, even though there is a small uptick in expected revenue growth.Uppdatering av berättelse • Nov 03
MRK: Future CEO Appointment Will Support Recovery and Restore Confidence
The analyst price target for Merck KGaA has been reduced from EUR 150 to EUR 130, as analysts cite softer growth expectations and recent earnings disappointments. Analyst Commentary Recent street research reflects a cautious tone among analysts regarding Merck KGaA, with a series of price target reductions and rating adjustments.Uppdatering av berättelse • Oct 20
Global Biotechnology And Digital Automation Will Drive Future Healthcare
Analysts have trimmed their fair value estimate for Merck KGaA from €147.53 to €145.94. This change reflects a series of recent price target reductions and persistent concerns regarding growth prospects and limited near-term catalysts.Uppdatering av berättelse • Sep 04
Global Biotechnology And Digital Automation Will Drive Future Healthcare
Merck KGaA's consensus price target remains unchanged at €147.53 as analysts adopt a more neutral stance following disappointing Q2 results, lowered guidance, and reduced near-term growth visibility. Analyst Commentary Disappointing Q2 report and weaker-than-expected operational performance.
Ny berättelse • Nov 24
AI-Driven Semiconductor Surge Powers Healthcare And Electronics To New Heights
Strong growth in semiconductor solutions and life sciences boosts Merck's Electronics and Process Solutions sectors, positively impacting future revenue and earnings.Aktieägarnas avkastning
| MRK | DE Pharmaceuticals | DE Marknad | |
|---|---|---|---|
| 7D | -5.1% | -4.6% | 0.2% |
| 1Y | 21.6% | 39.9% | 3.6% |
Avkastning vs industri: MRK presterade sämre än German Pharmaceuticals branschen som gav 39.9 % under det senaste året.
Avkastning vs Marknaden: MRK översteg German marknaden som gav 3.6 % under det senaste året.
Prisvolatilitet
| MRK volatility | |
|---|---|
| MRK Average Weekly Movement | 3.6% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 2.7% |
Stabil aktiekurs: MRK har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för German.
Volatilitet över tid: MRK s veckovolatilitet ( 4% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1668 | 62,136 | Kai Beckmann | www.emdgroup.com |
Merck KGaA verkar som ett vetenskaps- och teknikföretag i Tyskland. Verksamheten bedrivs genom segmenten Life Science, Healthcare och Electronics. Företagets Life Science-segment erbjuder verktyg, kemikalier och utrustning till akademiska laboratorier, bioteknik- och läkemedelstillverkare samt till industrisektorn.
Merck KGaA Sammanfattning av grunderna
| MRK grundläggande statistik | |
|---|---|
| Börsvärde | €59.26b |
| Vinst(TTM) | €2.37b |
| Intäkter(TTM) | €21.14b |
25.0x
P/E-förhållande2.8x
P/S-förhållandeÄr MRK övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| MRK resultaträkning (TTM) | |
|---|---|
| Intäkter | €21.14b |
| Kostnad för intäkter | €8.65b |
| Bruttovinst | €12.49b |
| Övriga kostnader | €10.12b |
| Intäkter | €2.37b |
Senast redovisade vinst
Jun 30, 2026
Nästa vinstdatum
Nov 12, 2026
| Vinst per aktie (EPS) | 5.45 |
| Bruttomarginal | 59.09% |
| Nettovinstmarginal | 11.21% |
| Skuld/egenkapitalförhållande | 38.5% |
Hur har MRK utvecklats på lång sikt?
Se historisk utveckling och jämförelseUtdelningar
1.6%
Aktuell utdelningsavkastning40%
UtbetalningskvotFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/14 05:54 |
| Aktiekurs vid dagens slut | 2026/08/14 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Merck KGaA bevakas av 42 analytiker. 13 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Odile Rundquist | Baader Helvea Equity Research |
| Gerhard Schwarz | Baader Helvea Equity Research |
| Charles Pitman | Barclays |